Juno Therapeutics jumps 53 after report Celgene is interested in buying the cancer drugmaker

Get the Full StoryMarkets Insider

Shares of Juno Therapeutics are up more than 50 in early trading on Wednesday following a Wall Street Journal report Tuesday evening that biotech giant Celgene is in talks to buy the cancer drugmaker.

Juno is developing a highly personalized cancer treatment called CAR T-cell therapy CAR is short for chimeric antigen receptor . 2017 was a big year for these treatments, with the Food and Drug Administration approving two, and Gilead Sciences buying CAR-T drugmaker Kite Pharma for 12 billion.

Celgene has been under pressure from investors to make some changes after a rocky 2017. Already in 2018, the company has acquired Impact Biosciences in a 7 billion deal, a move that didn't entirely excite the biotech community, Business Insider’s Lydia Ramsey reports.

Juno closed down 6.46 on Tuesday. Celgene is down 1.43 pre-market Wednesday.

NOW WATCH: PAUL KRUGMAN: Trump can't take credit for the soaring stock market

Share: